Cardiomyopathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with cancer and have been receiving immune checkpoint inhibitor (ICI) treatment for at least 3 months, with at least 2 doses received, and who have not developed any new heart or muscle symptoms, abnormal heart test (ECG) results, abnormal heart wall movement, or raised troponin (a marker of heart stress) since starting that treatment
- People who have signed an informed consent form before any trial procedures take place
- People who are covered by a social security scheme (excluding a specific type called AME)
Who may not be able to join:
- People under 18 years of age
- People who are pregnant or breastfeeding
- People who are under a legal protection or safeguarding measure
- For the MRI part of the study only: people who have a reason they cannot have an MRI scan, such as claustrophobia or certain metal implants or devices (for example, a pacemaker)
- For the MRI part of the study only: people who have had a reaction to gadolinium (an MRI contrast dye) or who have severely reduced kidney function (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Joe Elie SALEM, Pr, Assitance Publique - Hôpitaux de Paris
Phone: 01 42 17 85 35
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Identify common and rare variants in HLA regions and elsewhere in the genome associated with ICI Myocarditis.; Identify common and rare variants in HLA regions and elsewhere in the genome associated with ICI
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.